Literature DB >> 1746792

Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems.

J L Lami1, S E Wilson, J A Hopkins.   

Abstract

The authors report three trials of B-lactams and carbapenems for soft tissue infections treated on a surgical service: 1) cefmetazole versus cefoperazone, n = 44; 2) cefotetan versus cefoxitin, n = 24; and 3) meropenem versus imipenem, n = 44. A total of 138 hospitalized patients were enrolled with 112 meeting evaluability criteria. Four hundred twenty-three isolates were cultured (mean, three/patient) of which 67 per cent were aerobes and 33 per cent anaerobes. Cure rates for each trial were: 1) 93 per cent; 2) 92 per cent; 3) 100 per cent. Failures were caused by resistant organisms (Streptococcus group D, Bacteroides fragilis and Pseudomonas) appearing in incompletely drained infection sites. Three patients receiving meropenem had adverse effects (headache, nausea) and one receiving cefoxitin (truncal rash). Operative drainage and debridement remain the critical elements in therapy. Agents with longer half lives allowing twice daily dosing (cefmetazole and cefotetan) were as effective and less expensive than multiple doses of short-acting agents. The extended spectrum carbapenems are most useful for severe infections or resistant organisms.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1746792

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  3 in total

1.  Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery.

Authors:  K Kanellakopoulou; H Giamarellou; P Papadothomakos; H Tsipras; J Chloroyiannis; R Theakou; P Sfikakis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

Review 2.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

3.  Meropenem in the treatment of complicated skin and soft tissue infections.

Authors:  Douglas N Fish
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.